Oliver Freudenreich

Oliver Freudenreich, a psychiatrist from Massachusetts General Hospital and Harvard Medical School, delves into groundbreaking Finnish research that tracked 62,000 clozapine patients over 22 years. He discusses the rare side effect agranulocytosis, its long-term risks, and what this means for clozapine prescribing practices. Freudenreich compares clozapine to other antipsychotics, revealing its benefits and mortality rate advantages. The conversation highlights the urgent need for enhanced monitoring and better patient communication in mental health treatment.

Join psychiatrist Oliver Freudenreich, an expert in psychopharmacology from Massachusetts General Hospital, as he sheds light on the complexities of antipsychotic withdrawal. He discusses how psychotic relapse may sometimes be mistaken for withdrawal symptoms. The conversation reveals the common effects of discontinuation, such as insomnia and anxiety, along with risk factors and essential strategies for safe tapering. This insightful dialogue emphasizes the need for careful management and patient communication during this critical transition.

Oliver Freudenreich, a Boston-based psychiatrist and expert at the Psychopharmacology Institute, dives into the intriguing world of high-dose olanzapine as a potential alternative for treatment-resistant schizophrenia. The conversation highlights the challenges and risks associated with doses exceeding FDA limits. Oliver compares high-dose olanzapine to clozapine, discussing its efficacy based on a systematic review of various studies. They stress the necessity for patient-centered care, emphasizing informed discussions about long-term side effects like metabolism and weight gain.

Dr. Oliver Freudenreich, a Boston-based psychiatrist, dives into the fascinating world of probiotics and their potential to combat weight gain linked to antipsychotics like olanzapine. He discusses the probiotic Akkermansia muciniphila, suggesting it could be key to maintaining metabolic health. The conversation explores how gut health impacts weight management for patients on antipsychotics. Dr. Freudenreich also highlights the challenges of incorporating probiotics into treatment, paving the way for a holistic approach to psychiatric care.

In this engaging discussion, Oliver Freudenreich, a psychopharmacology expert, explores the revolutionary antipsychotic KarXT, which targets the cholinergic system instead of dopamine pathways. He shares insights from promising Phase 3 trial results, indicating KarXT's potential to treat schizophrenia with fewer motor-related side effects. This innovative approach not only showcases the drug's clinical efficacy but also discusses its potential FDA approval and implications for transforming how schizophrenia is managed.